Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

Eloralintide

NCT06230523

Eli Lilly · Phase 2 · Completed · Enrollment 263

NCT06230523

ArmPopulationDoseWeeksEstimandWeight change
PlaceboObesity, no T2Dn/r48Efficacy-0.4% at week 48
1 mg EloralintideObesity, no T2D1 mg48Efficacy-9% at week 48
3 mg EloralintideObesity, no T2D3 mg48Efficacy-12% at week 48
6 mg EloralintideObesity, no T2D6 mg48Efficacy-18% at week 48
9 mg EloralintideObesity, no T2D9 mg48Efficacy-20% at week 48
6/9 mg EloralintideObesity, no T2D6/9 mg48Efficacyn/r
3/6/9 mg EloralintideObesity, no T2D3/6/9 mg48Efficacyn/r